{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:55:13Z","timestamp":1790949313328,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100183","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T10:05:34Z","timestamp":1622714734000},"page":"100183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["How I treat medullary thyroid cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"B.","family":"Kiesewetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Riss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scheuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10061","key":"10.1016\/j.esmoop.2021.100183_bib1","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100183_bib2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100183_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","article-title":"Current understanding and management of medullary thyroid cancer","volume":"18","author":"Roy","year":"2013","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100183_bib4","doi-asserted-by":"crossref","first-page":"R499","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100183_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100183_bib6","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1210\/jc.2007-2496","article-title":"Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis","volume":"93","author":"Cheung","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100183_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1089\/thy.2005.15.1267","article-title":"Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders","volume":"15","author":"Vierhapper","year":"2005","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100183_bib8","doi-asserted-by":"crossref","first-page":"030710","DOI":"10.11613\/BM.2018.030710","article-title":"Calcium-stimulated calcitonin \u2013 the \u201cnew standard\u201d in the diagnosis of thyroid C-cell disease \u2013 clinically relevant gender-specific cut-off levels for an \u201cold test\u201d","volume":"28","author":"Niederle","year":"2018","journal-title":"Biochem Med (Zagreb)"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100183_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/thy.2019.0785","article-title":"Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays?","volume":"30","author":"Niederle","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100183_bib10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/00000478-200110000-00004","article-title":"Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients","volume":"25","author":"Kaserer","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100183_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/bjs\/znaa047","article-title":"Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction","volume":"108","author":"Niederle","year":"2021","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100183_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2021.100183_bib13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.esmoop.2021.100183_bib14","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100183_bib15","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100183_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100183_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100183_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2021.100183_bib21","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.28858","article-title":"Medical management of metastatic medullary thyroid cancer","volume":"120","author":"Maxwell","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100183_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","article-title":"Management of advanced medullary thyroid cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100183_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hed.26024","article-title":"Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2021.100183_bib24","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.12688\/f1000research.12645.1","article-title":"Recent advances in the biology and therapy of medullary thyroid carcinoma","volume":"6","author":"Nelkin","year":"2017","journal-title":"F1000Res"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2022.100516","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T20:28:57Z","timestamp":1625171337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921001435"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100183","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.esmoop.2022.100516","asserted-by":"object"}]},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat medullary thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100183"}}